



KELOWNA PROSTATE CANCER SUPPORT & AWARENESS GROUP

Contact information – email – sbren@telus.net

Phone – 250-762-0607

www.kelownaprostate.com

Publisher/Editor – Bren Witt

VOLUME 26 – ISSUE 1 – (Number 285) – SEPTEMBER 2023

Welcome back. WOW!! What a summer we just went through, excessive heat and then all the forest fires first starting in the North and then extending throughout the province. Our hearts go out to any of those who either lost homes or had their property damaged in the devastating forest fires, whether you lived in West Kelowna, Kelowna, the Shuswap, the Kootenays, or elsewhere in the province. This has been an extremely terrible year for forest fires.

Our meetings are still being held in the Harvest Room at Trinity Church, located at the corner of Springfield Rd. and Spall Rd. Everyone is welcome out to our meetings, if you know anyone who has been diagnosed with prostate cancer invite them out to a meeting, I think they may be surprised when they attend one of our meetings.

If anyone receiving this newsletter has any questions or concerns that I may be able to help with, please feel free to get in touch.

If you wish to have your contact removed for this contact list, please let me know and I will remove the information.

Janssen will Supply ESSA Pharma. with Apalutamide and Abiraterone Acetate to Conduct a Phase 1 Clinical Trial

The following information was obtained from the ESSA Pharma. website, as well as information off the Internet that was published in April 2023.

ESSA Pharma. is a Vancouver based pharmaceutical research company with offices also in Houston, Texas and San Francisco, California. ESSA's primary research efforts are focused on developing small molecule therapies to treat patients with androgen receptor (AR) – driven prostate cancer, with the focus on new treatment modalities targeting the N-terminal domain of the androgen receptor (NTD). ESSA's highly differentiated approach has the potential to bypass current AR-based resistance mechanisms that develop in patients with castration-resistant prostate can (CRPC) and metastatic castration-resistant prostate cancer (mCRPC).

Prostate Cancer is predominantly driven by the androgen receptor (AR). The current standard of care antiandrogen therapies target one end of the receptor (the ligand binding domain) which can lead to treatment resistance. EPI-7386, is a highly selective, oral, small molecule that inhibits the N-terminal domain of the AR, which is located at the opposite end of the receptor and is not targeted by any antiandrogen therapy.

ESSA Pharma. has signed a clinical trial support agreement with Janssen Research & Development to evaluate its EPI-7386 combinations for the treatment of men with prostate cancer.

As per the agreement, Janssen will supply ESSA with apalutamide and abiraterone acetate for a Phase1 clinical trial which will be conducted by ESSA pharma.

The trail study will evaluate the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumour activity of EPI-7386 when administered in combination with either apalutamide or abiraterone acetate plus prednisone.

Patients with metastatic castration-resistant prostate cancer (mCRPC) and high-risk metastatic castration-sensitive prostate cancer (mCSPC) will receive EPI-7386 along with abiraterone acetate plus prednisone in Cohort A of the phase 1 trial.

In Cohort B, investigators will assess the anti-tumour activity of

EPI-7386 for up to 12 weeks prior to the start of standard of care therapy in patients with non-metastatic CRPC. Patients will be dosed with a single agent EPI-7386 before adding standard-of-care apalutamide.

ESSA president and CEO David Parkinson said: “We are pleased to have this agreement in place in order to further investigate EPI-7386 in combination with apalutamide and abiraterone acetate plus prednisone in a variety of prostate cancer patient populations.

“Preliminary clinical data from EPI-7386 combination studies with standard-of-care antiandrogens in mCRPC patients have shown a favorable safety profile and encouraging early signs of anti-tumour activity.

“We look forward to examining EPI-7386 with apalutamide and abiraterone acetate with prednisone in additional prostate cancer populations to assess the safety, tolerability, optimal dose(s) and preliminary anti-tumour activities of these approaches.”

Across the globe, ESSA will retain all rights to the oral, small molecule inhibitor of the N-terminal domain of the androgen receptor, EPI-7386.

The company is also evaluating EPI-7386 in combination with enzalutamide in a Phase I/II trial, in metastatic CRPC patients who are yet to receive treatment with second-generation antiandrogen therapies.

Summary –

EPI-7386 is a unique investigational inhibitor of the N-terminal domain of the AR (androgen Receptor), with single agent activity observed in preclinical studies.

In preclinical studies, EPI-7386 has shown even more potency, a longer half-life, and improved pharmaceutical properties over the first-generation compound, EPI-506.

Combining EPI-7386 with anti-androgens suppresses AR-driven biology more broadly and deeply than with either approach alone in preclinical studies.

EDITORS NOTE: One of the original founders of ESSA Pharma. was Dr. Marianne Sadar Ph.D., a Prostate Cancer Researcher at BC Cancer in Vancouver. Dr. Sadar's work began with the aim to increase the efficacy of treatment for patients whose cancer has progressed to the most aggressive state. In 2007 after eight years of work, her laboratory team found a way to kill cancer cells and shrink tumours by using an androgen receptor molecule that interrupts a key step in cancer growth.

WITT'S WIT (ON THE LIGHTER SIDE)

Little Johnny

Little Johnny is always being teased by the other neighbourhood boys for being stupid. Their favorite joke is to offer Johnny

his choice between a nickel and a dime, Little Johnny always takes the nickel. One day, after Johnny takes the nickel, a neighbour takes him aside and says, "Johnny, those boys are making fun of you. Don't you know a dime is worth more than a nickel, even though the nickel's bigger?" Johnny grins and says, "Well, if I took the dime, they'd stop doing it, and so far, I've made \$20.!"

Can a Healthy Diet Prevent Prostate Cancer?

The following information was obtained from the Internet and was from a study published in *BJU International* one of the World's leading urology journals. This News Release was dated April 19, 2023.

A study published in *BJU International* found that adhering to a healthy diet seems to have no effect on prostate cancer risk, but following an unhealthy diet might increase the risk of developing aggressive prostate cancer.

The study assessed the diets of 15,296 men recruited in Spain from 1992-1996, among these men, 609 prostate cancer cases were identified during a median follow-up of 17 years. Diets were categorized as *Western, Prudent, or Mediterranean*. **The Western** dietary pattern consisted of a high intake of high-fat dairy products, processed meats, refined grains, sweets, caloric drinks, convenience foods and sauces, and a low intake of low-fat dairy products and whole grains. **The Prudent** dietary pattern was

characterized by a high intake of low-fat dairy products, vegetables, fruits, whole-grains, and juices. **The Mediterranean** dietary pattern represented a high intake of fish, vegetables, legumes, boiled potatoes, fruits, olives, and vegetable oil, and a low intake of juices.

No effect over prostate cancer risk was detected for the Prudent and Mediterranean dietary patterns, but a detrimental effect was observed with the Western dietary pattern. This effect was only observed for aggressive tumours.

“Our results indicate that avoiding unhealthy dietary habits could be the best nutritional strategy to prevent aggressive prostate cancer,” said lead author Adela Castelo-Pastor, PhD, of the Carlos III Institute of Health in Spain. “Substituting the intake of Western-type diet products by products characteristic of the Mediterranean diet could also decrease the risk of other chronic diseases,” added co-senior author Marina Pollan, PhD, of the Carlos III Institute of Health in Spain.

The information provided by the Spanish cohort of the European Prospective Investigation into Cancer and Nutrition – or – EPIC – has contributed to improving scientific knowledge of the relationship between diet and cancer and other chronic diseases,” added co-senior author Maria-Jose Sanchez, MD, PhD, lecturer at the Andalusian School of Public Health.

The Kelowna Prostate Cancer Support & Awareness group does not recommend treatment modalities or physicians: However, all information is fully shared and is confidential. The information contained in this newsletter is not intended to replace the services of your health professionals regarding matters of your personal health.

The Kelowna Prostate Cancer Support & Awareness Group would like to thank Janssen - and TerSera for their support and educational grants that go towards our newsletters and our support group.



UP COMING MEETING DATES FOR 2023 –

October 14, NOTE: - November 18, December 9 -

Meeting Location:

Our meetings take place in the Harvest Room at Trinity Church located at the corner of Springfield Road and Spall Road. Please enter through the South Entrance off the main parking lot and follow the signs upstairs to the Harvest Room. Our meetings begin at 9:00 A.M. and the doors open at 8:30 A.M. There is elevator access if needed.

NOTE: Many of our past newsletters are available for viewing and printing through our website. – www.kelownaprostate.com

- A big Thank You to Doris at Affordable Web Design for all her work on our website.